Study Among People Living With HIV and Their Health Professionals of Associated Factors of Resilience to Self-stigma
NCT ID: NCT05149001
Last Updated: 2023-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
667 participants
OBSERVATIONAL
2022-01-17
2022-04-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments
NCT05110963
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
NCT03661203
Predicting Treatment and Care Difficulties Among HIV Infected Patients
NCT02900599
ResIlience-based Stigma REdUction Program ("Rise-up")
NCT05174936
Stigma, Social Support and Quality of Life
NCT05781204
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary endpoint: Self-stigmatization as experienced by PLWHA will be explored through a patient questionnaire Secondary endpoints:The main explanatory variables will be studied by means of a custom questionnaire intended for the patient and covering psychological flexibility, social provisions, avoidance and fusion mechanisms, quality of life, anxiety and depression.
The socio-demographic explanatory variables will be collected by questionnaire, covering the following areas: sex, age, geographical origin, insecurity, drug use, sexuality, family context, employment, leisure, care environment.
A questionnaire intended for caregivers will study the self-stigmatization perception of the people they care for and the means implemented to fight against self-stigmatization.
Anonymous data will be reported in Redcap. The population will be described by numbers and percentages for categorical variables and by the mean ± standard deviation or the median \[interquartile range\] for the quantitative variables, with regard to their statistical distribution. Normality will be studied by the Shapiro-Wilk test and / or by histogram. As far as possible, graphical representations will be associated with the analyzes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Affiliation to a Social Security scheme For caregivers:Caregiver caring for people living with HIV as part of a hospital service involved in the survey (doctor, IDE, psychologist, other ...).
Exclusion Criteria
* Refusal of participation
* Persons under guardianship, guardianship or legal protection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Poissy-Saint Germain Hospital
OTHER
Centre Hospitalier Universitaire Dijon
OTHER
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
OTHER
Hopital Antoine Beclere
OTHER
Nantes University Hospital
OTHER
Hospital, La Roche sur Yon
UNKNOWN
Hôpital Necker-Enfants Malades
OTHER
Centre Hospitalier de Bretagne Sud
OTHER
Reims University hospital
OTHER
Groupe Hospitalier de la Rochelle Ré Aunis
OTHER
Hospital Laennec, Quimper
UNKNOWN
University Hospital, Brest
OTHER
Hospital Cornouaille, Quimper
UNKNOWN
Centre Hospitalier de Cholet
OTHER
University Hospital, Strasbourg
OTHER
CH Annecy Genevois
OTHER
Centre hospitalier de Perpignan
OTHER
Centre Hospitalier le Mans
OTHER
Centre Hospitalier VALENCIENNES
OTHER
Bicetre Hospital
OTHER
Centre Hospitalier Universitaire de Nice
OTHER
University Hospital, Marseille
OTHER
Jacques Lacarin Hospital Center
OTHER
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône
OTHER
Centre Hospitalier Universitaire de Besancon
OTHER
Hospital, Vannes
UNKNOWN
Moulins Hospital
OTHER
Hospital, Montluçon
UNKNOWN
Centre Hospitalier de Niort
OTHER
Hôpital Edouard Herriot
OTHER
Hospital La Source, Orléans
UNKNOWN
Centre Hospitalier du Pays d'Aix
OTHER
Hospital Andre Mignot, Le Chesnay
UNKNOWN
Hôpital Raymond Poincaré
OTHER
University Hospital, Angers
OTHER_GOV
University Hospital, Pointe-à-Pitre
UNKNOWN
Centre Hospitalier des Pays de Morlaix
OTHER
Hospital Foch, Suresnes
UNKNOWN
Tenon Hospital, Paris
OTHER
University Hospital of Saint-Etienne
OTHER
Centre Hospitalier de Saint-Denis
OTHER
University Hospital, Mulhouse
UNKNOWN
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christine JACOMET, Dr
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier du Pays d'Aix
Aix-en-Provence, , France
Chu Angers
Angers, , France
CH Annecy Genevois
Annecy, , France
Chru Besancon
Besançon, , France
CHRU Brest
Brest, , France
CH Cholet
Cholet, , France
Hopital Antoine Beclere
Clamart, , France
Clermont-Ferrand University Hospital
Clermont-Ferrand, , France
Chu Dijon
Dijon, , France
Hopital Raymond Poincaré
Garches, , France
CHD Vendrée
La Roche-sur-Yon, , France
Groupe Hospitalier de La rochelle-Ré-Aunis
La Rochelle, , France
CH de Versailles
Le Chesnay, , France
Hopital Bicetre Aphp
Le Kremlin-Bicêtre, , France
Ch Le Mans
Le Mans, , France
Centre Hospitalier Bretagne Sud
Lorient, , France
CHU LYON
Lyon, , France
CISIH
Marseille, , France
Ch Montlucon
Montluçon, , France
CH Morlaix
Morlaix, , France
CH Moulins-Yzeure
Moulins, , France
CHU de Mulhouse
Mulhouse, , France
Chu Nantes
Nantes, , France
CHU NICE
Nice, , France
CH NIORT
Niort, , France
CH Orléans
Orléans, , France
Hopitel Necker
Paris, , France
CH Perpignan
Perpignan, , France
Chu Poissy
Poissy, , France
CHU Poitiers
Poitiers, , France
Centre Hospitalier Intercommunal de Cornouaille
Quimper, , France
Pole Santé Publique - CH Laennec
Quimper, , France
Chu Reims
Reims, , France
CHU Nord
Saint-Etienne, , France
CHU Strasbourg
Strasbourg, , France
Hopital Tenon
Thenon, , France
Chu Toulon
Toulon, , France
Ch Valenciennes
Valenciennes, , France
CHBA Vannes
Vannes, , France
CH VICHY
Vichy, , France
Hôpital Nord Ouest villefranche sur Saone
Villefranche-sur-Saône, , France
CHU Pointe-à-Pitre
Pointe-à-Pitre, , Guadeloupe
CHU Felix Guyon
Saint-Denis, , Reunion
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A01588-33
Identifier Type: OTHER
Identifier Source: secondary_id
RNI 2021 JACOMET 2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.